Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III comparison of Gan & Lee insulin glargine versus Lantus in type 1 diabetes
2017-001450-34Phase 3Completed
- Sponsor
- Gan & Lee Pharmaceuticals
- Start
- Nov 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of insulin glargine in diabetes mellitus type 1 (T1D) (2 arms), sponsored by Gan & Lee Pharmaceuticals. Primary endpoint: Change in HbA1c at 26 weeks. Started Nov 2017; status: completed.
02
Drugs
insulin glargine
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on 2017-001450-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001450-34.